BRCA1 and cancer: <h4>Background</h4>Poly(ADP-ribose) polymerase inhibitors (PARPi) have transformed cancer therapy for patients harbouring homologous recombination repair (HRR) deficiencies, notably <i>BRCA1/2</i> mutations.